Cowen Reiterates Buy Rating for Orchard Therapeutics (NASDAQ:ORTX)

Orchard Therapeutics (NASDAQ:ORTX)‘s stock had its “buy” rating reissued by equities research analysts at Cowen in a research report issued on Monday, AnalystRatings.com reports. They currently have a $28.00 price target on the stock. Cowen’s price target points to a potential upside of 136.09% from the company’s previous close.

ORTX has been the subject of several other research reports. Barclays initiated coverage on shares of Orchard Therapeutics in a research report on Thursday, September 5th. They issued an “overweight” rating and a $21.00 price target for the company. Guggenheim began coverage on shares of Orchard Therapeutics in a research report on Tuesday, September 17th. They set a “buy” rating and a $31.00 price objective on the stock. Oppenheimer began coverage on shares of Orchard Therapeutics in a research report on Thursday, August 29th. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Orchard Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $24.71.

NASDAQ ORTX opened at $11.86 on Monday. The stock’s 50-day moving average price is $11.59 and its two-hundred day moving average price is $13.70. The company has a current ratio of 8.88, a quick ratio of 8.88 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.10 billion, a PE ratio of -1.16 and a beta of -1.18. Orchard Therapeutics has a 1 year low of $8.65 and a 1 year high of $21.64.

Orchard Therapeutics (NASDAQ:ORTX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. The firm had revenue of $1.92 million during the quarter, compared to analyst estimates of $0.53 million. Research analysts forecast that Orchard Therapeutics will post -1.83 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of ORTX. Granite Point Capital Management L.P. bought a new position in shares of Orchard Therapeutics during the 2nd quarter valued at $700,000. TD Asset Management Inc. increased its position in shares of Orchard Therapeutics by 95.0% during the second quarter. TD Asset Management Inc. now owns 87,666 shares of the company’s stock valued at $1,226,000 after purchasing an additional 42,717 shares during the period. Stanley Laman Group Ltd. acquired a new position in shares of Orchard Therapeutics in the second quarter valued at $256,000. Jabodon PT Co. raised its stake in shares of Orchard Therapeutics by 258.5% in the second quarter. Jabodon PT Co. now owns 110,248 shares of the company’s stock valued at $1,542,000 after purchasing an additional 79,496 shares in the last quarter. Finally, Monashee Investment Management LLC bought a new position in Orchard Therapeutics in the second quarter worth $3,078,000. Institutional investors own 69.25% of the company’s stock.

Orchard Therapeutics Company Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: Why investors pay attention to retained earnings

Analyst Recommendations for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.